Placebo for MORF-057

DRUG3 trials

Sponsors

Morphic Therapeutic Inc., Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

Conditions

Healthy VolunteersModerately to Severely Active Crohn’s DiseaseModerately to severely active ulcerative colitis

Phase 1

Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers

CompletedNCT04580745

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Healthy Volunteers

Start: 2020-09-23End: 2021-04-12Updated: 2025-08-01

Phase 2

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2)

Active, not recruitingCTIS2022-500953-17-00

Morphic Therapeutic Inc.Moderately to severely active ulcerative colitis

Start: 2023-03-23Target: 172Updated: 2025-12-11

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 2 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease (GARNET)

RecruitingCTIS2023-508158-24-00

Morphic Therapeutic Inc.Moderately to Severely Active Crohn’s Disease

Start: 2024-06-25Target: 150Updated: 2025-12-02

Related Papers

S793 Full Target Engagement With Saturation of α4β7 Integrin Receptor Occupancy Resulting in Changes in Subset of Lymphocytes by MORF-057 Following 200 Mg Daily Dosing in Healthy Subjects

The American Journal of Gastroenterology2022-10-01

P306 MORF-057, an oral selective α4β7 integrin inhibitor for Inflammatory Bowel Disease, leads to specific target engagement in a single and multiple ascending dose study in healthy subjects

Journal of Crohn s and Colitis2021-05-015 citations